Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: 2 | Rare Historical Photos

Biotech Sector May Flip to Market Leader by Year-End

As rate cuts loom and after years of lagging, the biotech sector is showing signs of life, with IBB outpacing the benchmark S&P 500 on the quarter.

MarketBeat

Is Gilead Sciences Stock Underperforming the Nasdaq?

Gilead Sciences has significantly outperformed the Nasdaq Composite over the past year, and analysts remain strongly bullish on the stock’s prospects.

Barchart

Options Corner: Why The Market Could Be Prescribing A Bull Call Spread For Gilead Sciences

While all publicly traded enterprises aim for business success, achieving it can also ironically lead to valuation pressures. That's the tough lesson that pharmaceutical giant Gilead Sciences, Inc. (NASDAQ:GILD) learned the hard way recently. Although the company delivered the goods for its latest financial disclosure, post-earnings digestion appears to have…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Gildea's Kite Pharma Just Acquired Interius—$350 Million Move Shakes Up Cancer Therapy

As biotechnology companies increasingly seek innovative approaches to enhance cancer treatment, strategic acquisitions are becoming a key pathway for expanding capabilities and integrating advanced therapeutic platforms. Kite Pharma, a Gilead Sciences Inc. company (NASDAQ:GILD) on Thursday agreed to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR…

Benzinga

CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans

CVS Health Inc. (NYSE:CVS) said it will not add Gilead Sciences Inc.’s (NASDAQ:GILD) new HIV prevention drug Yeztugo to its commercial plans.

Benzinga

The Saturday Spread: These 3 Stocks Statistically May Be Cooking Up Something Special (GILD, WMB, XPEV)

Forget interpreting financial data and news items. If you want real edge, you’ve got to consider the metrics the market isn’t paying attention to.

Barchart

Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

How To Earn $500 A Month From Gilead Sciences Stock Ahead Of Q2 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD) will release earnings results for the second quarter, after the closing bell on Thursday, Aug. 7.

Benzinga

Visa, Disney, Blackstone And A Health Care Stock On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Stephanie Link, Chief Investment Strategist at Hightower Advisors, picked Visa Inc. (NYSE:V) as her final trade.

Benzinga

This Gilead Sciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga

What to Expect From Gilead Sciences’ Q2 2025 Earnings Report

Gilead Sciences is expected to announce its fiscal second-quarter earnings next month, and analysts forecast a single-digit drop in its earnings.

Barchart

Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades'

In a rapidly evolving financial landscape, insights from top investment strategists and analysts can significantly influence market sentiment and investment strategies.

Benzinga

The Saturday Spread: Data-Driven Trades That Cut Through the Noise (GILD, MCD, DJT)

This weekend’s edition identifies three hot stocks that are flashing above-average upside probabilities with compelling multi-leg options strategies.

Barchart

US approves twice-yearly injection for HIV prevention – what you need to know about lenacapavir

The US Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that offers long-lasting protection against HIV infection. Administered once every six months, this new treatment marks a major advancement in expanding prevention options for people at risk of HIV infection.

The Conversation

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times UK

Marjorie Taylor Greene Buys Stocks Focusing on Tech, Energy, and a Biotech Firm That Recently Received FDA Approval for HIV Drug

US Congress member Marjorie Taylor Greene purchased shares of Adobe, Netflix, Snowflake, ServiceNow, NextEra Energy, and Gilead Sciences on 6th June.

International Business Times

US Approves Gilead's Twice-yearly Injection To Prevent HIV

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move the company hailed as a major breakthrough in the fight against the sexually transmitted virus.

Barchart

Is Gilead Sciences Stock Outperforming the S&P 500?

While Gilead Sciences has outperformed the S&P 500 Index over the past year, analysts are cautiously optimistic about the stock’s prospects.

Evening Standard

Alzheimer's and cold sores: Are they linked?

Could cold sores be linked to an increased risk of developing dementia? Could cold sore treatment be used to treat Alzheimer’s?

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Unusual Options Alert: The Smart Money is Piling Into Gilead Sciences (GILD)

While the new political paradigm might not be the most conducive environment for Gilead Sciences, positive sentiment is brewing for GILD stock.

MarketBeat

3 Biotech Giants Gaining From U.S. Sales and Policy Shifts

The significant domestic revenue base of select US biotech companies offers stability potential for investors navigating global trade complexities.

The Conversation

Prison needle programs could save double what they cost – our new modelling shows how

Needle and syringe programs are a proven public health intervention that provide free, sterile injecting equipment to people who use drugs. By reducing needle sharing, these programs help prevent the spread of blood-borne viruses such as hepatitis C and HIV and minimise life-threatening bacterial infections.

Barchart

Here's What to Expect From Gilead Sciences’ Next Earnings Report

Gilead Sciences is expected to announce its fiscal first-quarter earnings this month, and analysts forecast a robust triple-digit in its earnings.

Barchart

These 2 Buy-Rated Dividend Stocks Could Be Next in Line for a Trump Tariff Selloff. Should You Jump Ship Now?

Trump’s proposed tariffs on pharmaceutical imports from countries like Ireland and India have sparked concerns for companies like Amgen and Gilead Sciences.

Barchart

Gilead Sciences - Leader in HIV Medicines

Summary Gilead Sciences (GILD) shows strong technical buy signals, with a 19.60% gain since Trend Seeker's buy signal on 1/27 and a 50.31% gain in the last year. The company offers a diverse portfolio of medicines for HIV, COVID-19, liver diseases, oncology, and more, with significant collaborations enhancing its pipeline....

MarketBeat

These 3 Dividend Stocks Jumped 15% in a Month—More to Come?

Dividend stocks aren't just for long-term income generation. These three shares have jumped 15% in one month while also offering dividend payouts.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.